Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01345214 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia
A Phase 1 study, sponsored by Ono Pharma USA.
- Terminated
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT01345214 is a Phase 1 study that was terminated before completion, run by Ono Pharma USA. The registered enrollment target is 17 participants.
The verdict
NCT01345214, a Phase 1 study, was terminated before completion, sponsored by Ono Pharma USA.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of ONO-7746 across multiple doses in patients with solid tumors and chemotherapy induced thrombocytopenia (CIT) scheduled to receive at least two cycles of myelosuppressive chemotherapy on Day 1 every 21 days at the same dosages and schedule in the study. The secondary objectives are to characterize the PK profiles of ONO-7746 and to explore the pharmacodynamic effect of ONO-7746 on CIT.
Interventions
- DRUG ONO-7746
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2011-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01345214
The ClinicalTrials.gov registry entry for NCT01345214 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ono Pharma USA, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ONO-7746 is the first listed.
NCT01345214 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01345214 about?
NCT01345214 is a clinical study titled "A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia". The primary objective of this study is to evaluate the safety and tolerability of ONO-7746 across multiple doses in patients with solid tumors and chemotherapy induced thrombocytopenia (CIT) scheduled to receive at least two cycles of myelosuppressive chemotherapy on Day 1 every 21 days at the same ...
What is the current status of trial NCT01345214?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2011-05.
What interventions are being tested in trial NCT01345214?
The interventions under investigation include: ONO-7746 (DRUG).
Who is sponsoring clinical trial NCT01345214?
This trial is sponsored by Ono Pharma USA, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.